Novel microfluidic electrochemical biosensor for rapid diagnosis of biomarkers

免疫传感器在用于快速诊断体液中的生物标志物的不同类型的生物传感器中是非常已知的。免疫传感器的标记形式允许在广泛的检测方案中灵活地实施生物传感。然而，这些系统在非常高灵敏度的检测复杂的生物样品中的几分钟的分子方面受到限制。在将报告分子整合到基于标记的过程中的时间、成本和额外步骤方面也存在权衡。此外，在现场护理设备中使用光学检测系统在单个多重生物传感器中同时检测多个生物标志物方面具有另一个约束，因为它们需要外部光源、光学换能器和其他光学部件如透镜和反射器，这使得检测系统庞大且复杂。在各种无标记的检测技术中，电化学传感技术是最简单的集成技术，具有高度的灵敏度，并且与多路复用和集成到微流控中更兼容，这使得它成为床旁诊断的理想选择。将开发一种新的粘合技术，以非侵入性方式将电极粘附到微流体层上，从而实现电极的有效性能和生物标志物的即时检测。如果成功的话，本工作中提出的微流控纳米生物传感器将用于在不到一个小时的时间内快速诊断患者血液样品中的三种不同的脑损伤生物标志物。申请人在微流体和生物传感器方面的专业知识确保了该项目的成功。将受益于无标记生物传感器，以扩展其技术的应用，使用即时诊断技术快速和自动检测人体生物样本中的多种生物标志物。较低的成本和预测性的护理点传感器将使快速和大规模的疾病筛查成为可能，并有助于监测治疗的疗效，从而使加拿大的卫生系统受益。

Immunosensors are very known among different types of biosensors for rapid diagnosis of biomarkers in bodilyfluids. The label-format of immunosensors allows for flexible implementation of biosensing in a wide range ofdetection schemes. However, these systems are limited in very high sensitive detection of minutes of moleculesin complex biological samples. There is also a trade-off in the time, cost and additional steps associated withincorporating reporter molecules into the label-based process. Moreover, the use of optical detection systems inpoint-of-care devices has one more constraint in detection of multiple biomarkers simultaneously in a singlemultiplexed biosensor as they require an external light source, optical transducer and other optical componentslike lenses and reflectors, which makes the detection system bulky and complex. Among various types oflabel-free detection techniques, the electrochemical sensing is the simplest to integrate, highly sensitive andmore compatible with multiplexing and integration into microfluidics, which makes it ideal for point-of-carediagnosis.In this work, we will develop an integrated and autonomous microfluidic-based biosensor for rapid detection ofbrain injury biomarkers. A new bonding technology will be developed to adhere electrodes to microfluidiclayers noninvasively to enable efficient performance of electrodes and point-of-care detection of biomarkers. Ifsuccessful, the microfluidic nano-biosensor proposed in this work will be used for rapid diagnosis of threedifferent biomarkers of brain injury in blood samples of patients in less than an hour. The expertise of theapplicant in microfluidics and biosensors ensures the success of this project.Sensoreal Inc. will benefit from label-free biosensors to extend the application of their technology for rapid andautomated detection of multiple biomarkers in human biological samples using a point-of-care diagnostictechnology. The lower cost and predictive point of care sensors will enable the rapid and large scale diseasescreening and facilitate monitoring the efficacy of therapeutics, therefore benefit the health system in Canada.